Answers are grounded in this paper and cite their sources.
Cancer-associated fibroblasts (CAFs), as crucial stromal components in the tumor microenvironment, promote tumor progression and impair responses to immunotherapy. However, targeted therapies against CAFs remain limited in HPV-negative head and neck squamous cell carcinoma (HPV - HNSCC). Here, integrated analysis of single-cell RNA sequencing (scRNA-seq), bulk RNA sequencing, ChIP sequencing, and spatial transcriptomic data identified a candidate epigenetic fibroblast target. We revealed that SET and MYND domain-containing 3 (SMYD3) played a critical role in the transformation of fibroblasts into myofibroblasts. It promoted collagen production to impair infiltration of CD8 + T cells and upregulated THBS2 in CAFs to induce M2‑like macrophage polarization. Functional studies confirmed that targeting SMYD3 not only improved the immune environment but also enhanced the efficacy of anti‑PD‑L1 therapy in vivo. Our findings established SMYD3 as a central mediator of CAF-dependent immune suppression and nominated its inhibition as a promising strategy to improve immunotherapy outcomes in HPV - HNSCC.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: